Home > Insider Trading > Filing (0001209191-21-038980)

Filing Details

Accession Number:: 0001209191-21-038980
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2021-06-08 17:22:46
Reporting Period:: 2021-03-17

Accepted Time:: 2021-06-08 17:22:46
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1087294	Cumberland Pharmaceuticals Inc	CPIX	Pharmaceutical Preparations (2834)	000000000

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1408500	E Martin Cearnal	2525 West End Ave. Suite 950 Nashville TN 37203	Sr Vp/Chief Commercial Officer	Yes	Yes	No	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Disposition	2021-03-17	2,945	$3.22	148,814	No	4	F	Direct
Common Stock	Acquisiton	2021-04-16	105	$3.03	148,919	No	4	P	Direct
Common Stock	Acquisiton	2021-04-19	105	$3.04	149,024	No	4	P	Direct
Common Stock	Acquisiton	2021-04-20	105	$3.02	149,129	No	4	P	Direct
Common Stock	Acquisiton	2021-04-21	105	$2.97	149,234	No	4	P	Direct
Common Stock	Acquisiton	2021-04-22	105	$2.96	149,339	No	4	P	Direct
Common Stock	Acquisiton	2021-04-23	105	$2.99	149,444	No	4	P	Direct
Common Stock	Acquisiton	2021-04-26	105	$2.97	149,549	No	4	P	Direct
Common Stock	Acquisiton	2021-04-27	105	$2.94	149,654	No	4	P	Direct
Common Stock	Acquisiton	2021-04-28	80	$2.94	149,734	No	4	P	Direct
Common Stock	Acquisiton	2021-04-29	105	$2.89	149,839	No	4	P	Direct
Common Stock	Acquisiton	2021-04-30	105	$2.78	149,944	No	4	P	Direct
Common Stock	Acquisiton	2021-05-03	105	$2.66	150,049	No	4	P	Direct
Common Stock	Acquisiton	2021-05-04	105	$2.66	150,154	No	4	P	Direct
Common Stock	Acquisiton	2021-05-05	105	$2.73	150,259	No	4	P	Direct
Common Stock	Acquisiton	2021-05-06	105	$2.74	150,364	No	4	P	Direct
Common Stock	Acquisiton	2021-05-07	105	$2.73	150,469	No	4	P	Direct
Common Stock	Acquisiton	2021-05-10	105	$2.71	150,574	No	4	P	Direct
Common Stock	Acquisiton	2021-05-11	105	$2.68	150,679	No	4	P	Direct
Common Stock	Acquisiton	2021-05-12	105	$2.86	150,784	No	4	P	Direct
Common Stock	Acquisiton	2021-05-13	105	$2.88	150,889	No	4	P	Direct
Common Stock	Acquisiton	2021-05-14	105	$2.81	150,994	No	4	P	Direct
Common Stock	Acquisiton	2021-05-14	5,000	$2.77	155,994	No	4	P	Direct
Common Stock	Acquisiton	2021-05-17	105	$2.84	156,099	No	4	P	Direct
Common Stock	Acquisiton	2021-05-17	5,700	$2.83	161,799	No	4	P	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	F	Direct
No	4	P	Direct
No	4	P	Direct
No	4	P	Direct
No	4	P	Direct
No	4	P	Direct
No	4	P	Direct
No	4	P	Direct
No	4	P	Direct
No	4	P	Direct
No	4	P	Direct
No	4	P	Direct
No	4	P	Direct
No	4	P	Direct
No	4	P	Direct
No	4	P	Direct
No	4	P	Direct
No	4	P	Direct
No	4	P	Direct
No	4	P	Direct
No	4	P	Direct
No	4	P	Direct
No	4	P	Direct
No	4	P	Direct
No	4	P	Direct

Reported Derivative Transactions

Show Other Fields >>

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Options (right to buy)	Acquisiton	2021-03-17	5,000	$0.00	5,000	$3.22

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
5,000	2025-03-17	2031-03-17	No	4	A	Direct

Footnotes

This transaction represents shares withheld/purchased by the Company to cover the tax withholding obligations for the vesting of shares.
The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2021.
The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $2.715 to $2.792, inclusive. The reporting person undertakes to provide to Cumberland Pharmaceuticals Inc., any security holder of Cumberland Pharmaceuticals Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnotes (3) and (4) to this Form 4.
The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $2.805 to $2.8797, inclusive.
100% vesting on March 17, 2025.